Kairos Pharma (KAPA) Net Margin (2024 - 2025)

Kairos Pharma's (KAPA) quarterly Net Margin came in at 3.23% in Q2 2025, down 4.13% on a QoQ basis from 3.1% in Q1 2025.

Kairos Pharma (KAPA) Net Margin (2024 - 2025) Analysis & Trends

Kairos Pharma (KAPA) has 2 years of Net Margin data on file, last reported at 3.23% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.65 Bn	131.79 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.08 Bn	78.09 Bn	3.93 Bn	30.23%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	31.16%
4	Moderna	63.25 Bn	58.11 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.26 Bn	27.95 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.96 Bn	10.57 Bn	668.28 Mn	-16.51%
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.19 Bn	26.35 Bn	-	12.09%
10	Kairos Pharma	5.55 Mn	218,135.11	-	-

Download Data